ArticleCureus2025
Intravascular Large B-cell Lymphoma Presenting as Hemophagocytic Lymphohistiocytosis and Pyrexia of Unknown Origin: A Diagnostic Dilemma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravascular large B-cell lymphoma (IVBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma distinguished by the proliferation of malignant lymphoid cells within the lumina of small vessels. Its unusual growth pattern results in absent lymphadenopathy and nonspecific imaging findings, often leading to delayed diagnosis. We report the case of a 71-year-old man who presented with prolonged fever, hepatosplenomegaly, anemia, leukopenia, thrombocytopenia, and markedly elevated ferritin. He was diagnosed with secondary hemophagocytic lymphohistiocytosis (HLH) and initially improved with HLH-directed immunosuppressive therapy but soon deteriorated again. PET-CT showed only diffuse hepatic and splenic uptake without discrete lesions. A bone marrow biopsy revealed IVBCL. This case highlights the diagnostic challenges of IVBCL, particularly its overlap with HLH, the limitations of PET-CT, and the crucial role of bone marrow biopsy. Early detection and initiation of therapy remain essential for improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.